Today: Apr 2, 2023
RU / EN
Last update: Feb 28, 2023
Pancreatic Neuroendocrine Tumors: a Modern Approach to Treatment

Pancreatic Neuroendocrine Tumors: a Modern Approach to Treatment

Kuchin D.M., Seregin A.A., Zagainov V.E.
Key words: neuroendocrine tumor; pancreatectomy; hepatic artery chemoembolization.
2019, volume 11, issue 3, page 75.

Full text

html pdf
2689
912

The aim of the study was to evaluate efficacy of combined treatment for well-differentiated pancreatic neuroendocrine tumors according to the data provided by a specialized center.

Materials and Methods. Treatment of 40 patients with pancreatic neuroendocrine tumors was assessed. All of the patients underwent surgical removal of the primary tumor. Liver metastases (stage IV) were diagnosed in 14 patients, postoperative courses of hepatic artery chemoembolization were performed in 12 patients, and 10 of them had well-differentiated cancer.

Results. Good survival rates in patients with stage IV disease (n=12) are comparable with those in the group of patients with stage III (n=6) provided tumors are well-differentiated and courses of intra-arterial hepatic chemoembolization are given. In patients with poorly differentiated neuroendocrine tumors (n=7), there was progression within a short time, but survival was less than 1-year after surgery despite active management.

Conclusion. To manage well-differentiated pancreatic neuroendocrine tumors, aggressive surgical approach should be used, despite the presence of metastatic lesions. In management of poorly differentiated neuroendocrine cancer, surgical approach proves to have unsatisfactory long-term results.

  1. Onkologiya. Klinicheskie rekomendatsii [Oncology. Clinical guidelines]. Pod red. Davydova M.I. [Davydov M.I. (editor)]. Moscow: Izdatel’skaya gruppa RONTs; 2015; 680 p.
  2. Chen C., Yi X., He Y. Gastro-entero-pancreatic neuroendocrine tumor (GEP-Nets): a review. J Gastrointest Dig Syst 2013; 3(5): 2161–2169, https://doi.org/10.4172/2161-069x.1000154.
  3. Lairmore T.C., Quinn C.E., Martinez M.J. Neuroendocrine tumors of the pancreas: molecular pathogenesis and current surgical management. Transl Gastrointest Cancer 2014; 3(1): 29–43.
  4. McKenna L.R., Edil B.H. Update on pancreatic neuroendocrine tumors. Gland Surg 2014; 3(4): 258–275.
  5. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A., Evans D.B. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26(18): 3063–3072, https://doi.org/10.1200/jco.2007.15.4377.
  6. Simonenko V.B., Dulin P.A., Makanin M.A. Kartsinoidy i neyroendokrinnye opukholi [Carcinoid and neuroendocrine tumors]. Moscow: Meditsina; 2008; 176 p.
  7. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62(1): 51–58, https://doi.org/10.1159/000051856.
  8. Granov D.A., Pavlovskiy A.V., Popov S.A., Polikarpov A.A., Moiseenko V.E. Combined treatment of patients with pancreatic neuroendocrine carcinomas. Annaly khirurgicheskoy gepatologii 2016; 21(1): 32–37, https://doi.org/10.16931/1995-5464.2016132-37.
  9. Glotov A.V., Kalinin D.V., Smirnov A.V., Kriger A.G. Staging of pancreatic neuroendocrine tumor (literature review). Annaly khirurgicheskoy gepatologii 2017; 22(3): 70–76, https://doi.org/10.16931/1995-5464.2017370-76.
  10. Ho A.S., Picus J., Darcy M.D., Tan B., Gould J.E., Pilgram T.K., Brown D.B. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188(5): 1201–1207, https://doi.org/10.2214/ajr.06.0933.
  11. Strosberg J.R., Cheema A., Weber J., Han G., Coppola D., Kvols L.K. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29(22): 3044–3049, https://doi.org/10.1200/jco.2011.35.1817.
  12. Yang M., Zeng L., Zhang Y., Wang W.G., Wang L., Ke N.W., Liu X.B., Tian B.L. TNM staging of pancreatic neuroendocrine tumors. Medicine 2015; 94(12): e660, https://doi.org/10.1097/md.0000000000000660.
  13. Lesurtel M., Nagorney D.M., Mazzaferro V., Jensen R.T., Poston G.J. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB 2015; 17(1): 17–22, https://doi.org/10.1111/hpb.12225.
  14. Rossi R.E., Massironi S., Conte D., Peracchi M. Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med 2014; 2(1): 8.
  15. Gurevich L.E., Korsakova N.A., Voronkova I.A., Ashevskaya V.E., Titov A.G., Kogoniya L.M., Egorov A.V., Britvin T.A., Vasil’ev I.A. Immunohistochemical determination of expression of somatostatin receptors types 1, 2A, 3 and 5 in neuroendocrine tumors of various localization and grade. Al’manah kliniceskoj mediciny 2016; 44(4): 378–390, https://doi.org/10.18786/2072-0505-2016-44-4-378-390.
  16. Laskaratos F.M., Caplin M. Treatment challenges in and outside a network setting: gastrointestinal neuroendocrine tumours. Eur J Surg Oncol 2019; 45(1): 52–59, https://doi.org/10.1016/j.ejso.2018.03.012.
Kuchin D.M., Seregin A.A., Zagainov V.E. Pancreatic Neuroendocrine Tumors: a Modern Approach to Treatment. Sovremennye tehnologii v medicine 2019; 11(3): 75, https://doi.org/10.17691/stm2019.11.3.10


Journal in Databases

pubmed_logo.jpg

web_of_science.jpg

scopus.jpg

crossref.jpg

doaj.jpg

ebsco.jpg

embase.jpg

ulrich.jpg

cyberleninka.jpg

e-library.jpg

lan.jpg

ajd.jpg

vak.jpg